Java Brucea (Brucea javanica (L.) Merr.): A Comprehensive Reference
1. Identity and Botanical Description
1.1 Scientific and Common Names
Brucea javanica (L.) Merr. is a plant in the Simaroubaceae family, and the medicinal ingredient is derived from its dried mature fruit. The species is commonly called Java brucea, Java bruise nut, or Kosam in English. The medicinal part used is the dry and ripe fruits, known in the pharmacopeial literature as Fructus Bruceae, which is commonly called Ya-Dan-Zi (鸦胆子) in Chinese. In the Indo-Malay region the seeds are known as Melada pahit, meaning "bitter medicine."
1.2 Botanical Synonyms
Numerous synonyms are recorded in the historical botanical literature. Accepted synonyms include Ailanthus gracilis Salisb., Brucea amarissima Desv. ex Gomes, Brucea amarissima (Lour.) Merr., Brucea glabrata Decne., Brucea gracilis (Salisb.) DC., Brucea sumatrana Roxb., Brucea sumatrensis Spreng., Gonus amarissimus Lour., Lussa amarissima (Lour.) Kuntze, Rhus affinis Wall., Rhus amela D.Don, Rhus bucki-amela Roxb., Rhus fastuosa Salisb., and Tetradium amarissimum Poir.
1.3 Geographic Distribution
B. javanica is distributed widely throughout the tropical and subtropical zones of China, including Guangdong, Guangxi, Yunnan, and Fujian provinces. The plant is a 3-metre-tall shrub that is mostly found in India, Southeast Asia, and Northern Australia. Its range also extends across sub-Saharan Africa, parts of East Africa, and the Pacific Islands, reflecting its broad pantropical distribution.
1.4 Common Preparations and Dosage Forms
B. javanica encompasses a diverse range of metabolites and various formulations. It has been commercially available in many forms, such as BJOE injection, BJO oral emulsion, and BJO soft capsules. Brucea javanica oil (BJO) is the active substance extracted from the dry and mature fruit of Brucea javanica. Its pharmaceutical preparation, BJO emulsion (BJOE), is one of the most widely studied traditional Chinese medicine preparations for the treatment of malignancy. Beyond these commercial preparations, the plant's seeds are also prepared as crude oral doses (whole seeds or kernels enclosed in capsule shells to protect against gastric irritation), aqueous decoctions, and ethanolic or hydroethanolic extracts used in research settings.
2. Traditional and Historical Use
2.1 Chinese Medicine
Brucea javanica (Ya-dan-zi in Chinese) is a well-known Chinese herbal medicine, which is traditionally used in Chinese medicine for the treatment of intestinal inflammation, diarrhea, malaria, and cancer. The first record of its use in Chinese medicine appeared in the book titled The Omissions from the Compendium of Materia Medica (Ben-Cao-Gang-Mu-Shi-Yi) in the Qing Dynasty. A separate source dates the initial Chinese herbal record to 1711 CE: Brucea javanica was first recorded in Shengcao Yaoxing Beiyao, compiled by Jian He in the Qing Dynasty (1711 CE).
The drug source comes from the dried ripe fruit of Brucea javanica (L.) Merr., which belongs to the plant genus Brucea of the Simaroubaceae family. It is described as bitter in taste and cold in nature — properties that in Chinese medical theory align it with clearing heat, drying dampness, and resolving toxicity.
Fructus Bruceae is recorded in the Chinese Pharmacopoeia for treating many diseases, including intestinal inflammation, diarrhea, malaria, and different types of cancer. Moreover, B. javanica is also described in the literature as useful for diseases such as abdominal pain, hyperkeratosis, hemorrhoids, and ulcers.
It has been used in traditional Chinese medicine for a long time as an antimalarial and antidysenteric agent. By external application, it was also used for the treatment of warts and corns.
2.2 Traditional Use Across Asia
Brucea javanica is a well-known medicinal herb in Asia, used in Chinese traditional medicine and in local medicine. All parts of the plant, but most often the seeds and roots, are used, mainly in the treatment of amoebic dysentery, diarrhoea, and malaria.
B. javanica seeds, known as "Melada pahit" in the Indo-Malay region, are traditionally used to treat diabetes. In traditional folk medicine, the seed of this plant has been used for the treatment of diabetes and various disorders among indigenous peoples of the Malayan peninsula.
In Chinese herbal medicine, the kernels are prescribed in amoebic dysentery and as a remedy for intestinal worms. Although there is no record of the kernels being used in Australian traditional medicine, the leaves and roots were used as an analgesic by Aborigines in north Queensland.
In addition to its use in treating dysentery, malaria, and related conditions, the plant is also used in the treatment of abdominal pains, coughs, haemorrhoids, corns, warts, ulcers, and cancer.
3. Phytochemistry: Key Constituents
3.1 Overview of Chemical Classes
To date, approximately 200 distinct chemical constituents have been isolated and identified from B. javanica, mainly comprising quassinoids, triterpenes, alkaloids, steroids, phenylpropanoids, and flavonoids. More than a hundred chemical compounds have been isolated and identified from different parts of this plant, and the main chemical classes of these isolates include quassinoids, alkaloids, and triterpenoids.
In recent decades, B. javanica has been subjected to intensive phytochemical investigations, and many chemical constituents, such as tetracyclic triterpene quassinoids, olein, oleic acid, linoleic acid, anthraquinone, alkaloids, and triterpenoids have been identified in this plant.
3.2 Quassinoids — the Primary Bioactive Class
Especially, tetracyclic triterpene quassinoids are the main bioactive ingredients of B. javanica with potent antitumour activity. Quassinoids, including approximately 110 compounds, are the main characteristic bioactive constituents.
The most studied individual quassinoids include:
- Brusatol — a triterpene lactone compound that sensitizes a broad spectrum of cancer cells and is known as a specific inhibitor of the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway.
- Bruceine D — one of the two major bioactive compounds alongside brusatol, possessing many pharmacological activities, including anti-cancer, anti-diabetic, antiviral, anti-inflammatory, and anti-bacterial properties.
- Bruceantin — exhibits the most potent antimalarial activity among the metabolites investigated, consistent with findings from the University of London School of Pharmacy.
- Bruceantinol — reported to exhibit potent antineoplastic activity alongside bruceantin.
- Bruceines A, B, C, E, F, H and various yadanziolides (e.g., yadanziolide B, S, T) — a series of additional quassinoid compounds isolated from the seeds and fruits. The new quassinoid yadanziolide S was isolated from the seeds along with ten known compounds including flazin, bruceine D, yadanziolide B, bruceoside A, yadanzigan, glycerol 1,3-bisoleate, azelaic acid, and vanillin.
- Javanicosides — four quassinoid glucosides, javanicosides I, J, K, and L, isolated from B. javanica, showed moderate cytotoxic activity on P-388 murine leukemia cells, with IC50 values of 7.5, 2.3, 1.6, and 2.9 μg/ml, respectively.
3.3 Fatty Acids and Lipids
The seed oil of B. javanica is rich in lipid constituents. Chemical constituents identified include olein, oleic acid, and linoleic acid alongside anthraquinones. These fatty acid components are primary constituents of the commercially manufactured Brucea javanica oil emulsion (BJOE) used in clinical settings in China.
3.4 Alkaloids, Flavonoids, and Polyphenols
B. javanica is rich in chemical constituents including quassinoids, triterpenes, alkaloids, and flavonoids. The bioactive fraction of the seeds also yields individual polyphenolic compounds. Chromatographic isolation of the ethyl acetate fraction of the seeds led to the identification of seven compounds: vanillic acid, bruceine D, bruceine E, parahydroxybenzoic acid, luteolin, protocatechuic acid, and gallic acid.
4. Mechanisms of Action
4.1 Brusatol: Nrf2 Pathway Inhibition
Numerous studies have shown that brusatol is a unique nuclear factor erythroid 2-related factor 2 (Nrf2) inhibitor that acts on various signaling pathways and has good antitumor properties. Brusatol was found to reduce the Nrf2 protein level by enhancing ubiquitination and degradation of Nrf2 in a Keap1-independent way. Because Nrf2 is an important transcription factor that confers chemotherapy resistance in cancer cells, its inhibition by brusatol has been proposed as a mechanism for sensitizing tumors to standard cytotoxic agents.
Brucea javanica triggers the generation of reactive oxygen species (ROS), release of cytochrome C, activation of the mitochondrial apoptosis pathway, and regulation of a series of signal pathways and proteins related to cancer. The molecular mechanisms involved include inhibiting the PI3K/Akt/mTOR, NF-κB, and Nrf2-Notch1 pathways; up- or down-modulating the levels of p53, p62, p21, Bax, and Bcl-2 respectively; and inhibiting the expression of matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2).
Brusatol possesses biological and medical activity, including antitumor, antileukemia, anti-inflammatory, antitrypanosomal, antimalarial, and antitobacco mosaic virus activity.
4.2 Bruceine D: Multiple Targets
Bruceine D was reported to markedly improve the loss of dopaminergic neurons in the substantia nigra pars compacta and alleviate neuroinflammation through reducing glial activation in an MPTP-induced mouse model of Parkinson's disease. Oxidative stress in MPTP mice was also attenuated after bruceine D treatment, and the mechanism of action was associated with improving the Nrf2 activation.
Furthermore, bruceine D could improve spinal muscular atrophy (SMA) through enhancing the survival of motor neuron 2 (SMN2) splicing, contributed by a reduction in the expression of heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). The findings suggest a good potential for developing bruceine D into a plant-derived SMA treatment.
4.3 Antidiabetic Mechanisms
A hydroethanolic extract of B. javanica seeds was fractionated and an active fraction was selected after screening for its ability to inhibit α-glucosidase and glycogen phosphorylase α (GP-α). Luteolin was identified as the most potent inhibitor of GP-α and α-glucosidase enzymes, followed by para-hydroxybenzoic acid, protocatechuic acid, and gallic acid. Inhibition of these two enzymes is mechanistically relevant to postprandial blood glucose regulation.
4.4 Anti-inflammatory Mechanisms
The ethanolic extract of B. javanica fruit exhibited anti-inflammatory activity at an oral intake of 50 mg/kg, inhibiting rat paw edema by 50.91% compared to celecoxib at 58.52%. Moreover, B. javanica showed COX-2 inhibition by 16.40% compared to celecoxib by 20.50%, indicating that B. javanica fruit extracts have promising anti-inflammatory activity directed against COX-2 enzymatic activity.
4.5 Antiviral Mechanisms
Brucea javanica oil emulsion (BJOE) at concentrations at or below 5 mg/ml was nontoxic to carcinoma cell lines, but could significantly inhibit both wild-type and lamivudine-resistant HBV replication and HBs/e/c antigen expression in a dose-dependent manner by upregulating interleukin-6 (IL-6), demonstrating moderate anti-HBV activity. Bruceine B was shown to be responsible for the IL-6 upregulation and anti-HBV activity.
5. Scientific Evidence by Area of Use
5.1 Oncology / Anti-Cancer Applications
5.1.1 Preclinical (In Vitro and Animal) Evidence
Numerous studies have reported that B. javanica exerts anticancer effects on various types of cancer cell lines through inhibiting cell proliferation, inducing apoptosis, inhibiting migration/invasion, inducing autophagy, and restraining angiogenesis. B. javanica triggers the generation of ROS, release of cytochrome C, and activation of the mitochondrial apoptosis pathway.
Brusatol and bruceine D are two important bioactive compounds. Brusatol and bruceine D exhibited potent cytotoxicity on several cell lines of pancreatic cancer, with IC50 values of 0.36 µM (PANC-1)/0.10 µM (SW 1990) for brusatol and 2.53 µM (PANC-1)/5.21 µM (SW 1990) for bruceine D, respectively.
Brusatol also showed anti-cancer activity in head and neck squamous cell carcinoma, melanoma, and laryngeal cancer through inhibiting STAT3 and the Nrf2 signaling pathways and abrogating JAK2/STAT3 signaling-mediated EMT process, respectively.
In intestinal cancer cells, Bruceanol D, E, and F exhibited cytotoxicity against HCT-8 ileocecal adenocarcinoma with ED50 values of 0.16–0.67 μmol/L. Brusatol, Bruceine B, BD, and Yadanziolide A were evaluated for cytotoxicity against SW480 cell lines with IC50 values of 0.1–28.5 μmol/L. Yadanziolides T, Yadanziolide B, and Bruceines B, D, E, and H exhibited cytotoxicity against HCT-8 with IC50 values of 1.3–6.7 μmol/L.
Brusatol serves as a sensitizer when combined with other anticancer regimens. Monotherapy of brusatol could be effective for certain types of cancers that have a high burden of oxidative stress. Although targeting specificity and systemic toxicity remain issues, numerous findings have shown that targeting the NRF2 defensive mechanism could be a novel therapeutic strategy for human malignancies.
Evidence strength: Extensive in vitro and animal model data; no completed human clinical trials specifically testing isolated brusatol or bruceine D in oncology.
5.1.2 Clinical Evidence: Brucea javanica Oil Emulsion Injection (BJOEI)
Brucea javanica oil emulsion injection (BJOEI), an extract of ripe fruit from Brucea javanica, has been widely applied in cancer treatment for many years in China. According to pharmacological research, the anticancer functions of BJOEI are mainly focused on inducing apoptosis or autophagy, inhibiting proliferation, invasion, migration, or angiogenesis, and enhancing radiosensitivity. Additionally, BJOEI as adjuvant therapy has also shown superiority in efficacy and safety for cancer treatment in clinical practice.
Gastric cancer (meta-analysis): Eighteen RCTs involving 1,210 patients were included in one systematic review and meta-analysis; results demonstrated that, compared with conventional therapy alone, BJOEI combined with conventional therapy showed a significantly improved overall response rate (ORR) (RR = 1.52, 95% CI: 1.36–1.69, P < 0.00001), clinical benefit rate (CBR) (RR = 1.17, 95% CI: 1.11–1.23, P < 0.00001), performance status (RR = 1.72, 95% CI: 1.46–2.01, P < 0.00001), and reduced incidence of adverse drug reactions including neutropenia, leukopenia, nausea and vomiting, diarrhea, liver damage, hand-foot syndrome, and peripheral sensory nerve toxicity.
Based on the GRADE criteria, the ORR, CBR, performance status, and ADRs were all assessed as low-quality evidence, owing to the existence of clinical heterogeneity and low participant numbers in most studies. The conclusion supports the fact that BJOEI combined with conventional chemotherapy provides a statistically significant and clinically important effect, but more rigorously designed, large-scale, and multicenter RCTs are needed.
Liver cancer (TACE combination): A meta-analysis was conducted to determine the efficacy and safety of BJOE combined with transcatheter arterial chemoembolization (TACE) in treating moderate or advanced primary liver cancer. The results showed that BJOE (30 ml/d) combined with TACE significantly increased overall efficacy, 2-year survival rate, quality of life, and decreased the incidence of leukopenia (p < 0.05) when compared with TACE alone.
Lung cancer: Injection of Brucea javanica oil emulsion (IBJOE) has been widely used for lung cancer in China and is known to provide some favorable outcomes, particularly when combined with conventional treatment. However, little available high-quality evidence is known about its effect and safety. In available studies, the IBJOE group had better immune function than the control group in terms of levels of CD3+ and CD4+, one-year survival rate, and reduction of incidences of grade III–IV leucopenia and gastrointestinal reactions.
Esophageal cancer: A pooled analysis of 1,269 cases evaluated the effects of javanica oil emulsion injection combined with radiotherapy versus radiotherapy alone on efficacy and safety in patients with esophageal cancer.
Cervical cancer: Accumulating clinical studies indicate that BJOE combined with conventional chemotherapy could provide more beneficial effects than chemotherapy alone for patients with various types of cancer, including lung, gastric, and liver cancers. BJOE has been found to induce cytotoxicity in HPV-positive cervical cancer cells selectively by targeting the apoptosis mechanism, suggesting its therapeutic potential for cervical cancer. However, the amount of evidence remains limited and the underlying mechanisms have not been fully elucidated.
Overall oncology evidence strength: Statistically significant results exist from meta-analyses of RCTs conducted in China, but GRADE assessments rate the evidence quality as low, primarily due to heterogeneity, methodological limitations of constituent studies, small sample sizes, and limited independent replication outside China. No regulatory approvals exist in Western countries. Isolated compounds (brusatol, bruceine D) remain in preclinical development.
5.2 Antimalarial Activity
B. javanica has anti-plasmodium activity and is often used in traditional applications for the treatment of malaria. The anti-insect effects of B. javanica mainly include anti-Plasmodium, anti-Babesia, anti-Trypanosoma, and the ability to kill Culex fumigatus. Among the metabolites, brusatol exhibits various functions including anti-malarial, anti-trypanosome, and mosquito-killing properties against Culex mosquitoes.
A study investigated the antimalarial activities of B. javanica against Plasmodium falciparum, the major species associated with severe malaria. Malaria parasites were treated with plant extracts using single and co-incubation methods along with artesunate and chloroquine; all tested doses of the extracts that effectively inhibited malaria parasites did not cause hemolysis of red blood cells. The root extract and fruit extract inhibited parasite growth at IC50 values of 0.41 ± 1.14 µg/mL and 0.26 ± 1.15 µg/mL, respectively.
Root and fruit water extracts elicited an additive effect with artesunate and chloroquine, significantly reducing IC90 levels for the inhibition of parasite development. In conclusion, B. javanica extracts inhibited the asexual blood-stage development of malaria parasites and showed additive effects with conventional antimalarial drugs, elucidating their potential for further studies on novel antimalarial drug regimens.
Evidence strength: Substantial in vitro evidence and historical traditional use, but no modern controlled clinical trials in human malaria have been identified.
5.3 Antidiabetic / Blood Glucose Regulation
B. javanica seeds are traditionally used to treat diabetes in the Indo-Malay region. One published study aimed to determine the antidiabetic, antioxidant, and anti-inflammatory effects of B. javanica seeds on nicotinamide (NA)-streptozotocin (STZ)-induced type 2 diabetic (T2D) rats and to analyze the chemical composition correlated with these pharmacological activities.
An ethyl acetate fraction exerted dose-dependent inhibition of GP-α (IC50 = 0.75 mg/ml). Further evaluation of the hypoglycaemic effect indicated that rats treated with the ethyl acetate fraction (125 mg/kg body weight) showed a 39.91% decrease in blood glucose levels at 30 min, and a continuous fall of 28.89% and 20.29% was observed in the following hours (60 and 90 min) compared to the normal control during an oral glucose tolerance test.
Bioactivity-guided fractionation in a separate study led to the isolation of bruceines E and D. Normoglycaemic mice administered with 1 mg/kg of bruceines E and D exhibited significant blood glucose concentration reductions of 40.07 ± 11.45% and 48.82 ± 13.34%, respectively.
Evidence strength: Preliminary; confined to in vitro enzyme inhibition assays and rodent models. No human clinical trials are available for the antidiabetic indication.
5.4 Anti-inflammatory Activity
In addition to the COX-2 data described under mechanisms, brusatol possesses anti-inflammatory activity as demonstrated in multiple laboratory studies. The inhibition of pro-inflammatory mediators including COX-2, PGE2, VEGF, and NF-κB signaling (see Section 4) supports a broad mechanistic basis for anti-inflammatory effects, all of which are documented at the preclinical level only.
Evidence strength: Preclinical (animal and cell-based) only. No human trials for isolated inflammatory conditions have been identified.
5.5 Antiviral Activity (Hepatitis B)
BJOE showed the same antiviral effect on both wild-type and lamivudine-resistance mutant HBV, benefiting from different antiviral mechanisms than nucleoside analogues. Taken together, BJOE has promising therapeutic potential for chronic hepatitis B patients, either alone or in combination with nucleoside analogues. Furthermore, BJOE may play a dual role for cancer patients combined with HBV infection.
Evidence strength: In vitro cell-line data only. No controlled clinical trials evaluating BJOE or any constituent for hepatitis B in humans have been identified in the peer-reviewed literature retrieved.
5.6 Neurology: Spinal Muscular Atrophy (SMA) and Parkinson's Disease Models
BJ extract and bruceine D can effectively correct splicing errors in surviving motor neuron 2 (SMN2) and alleviate symptoms related to spinal muscular atrophy in mice. This was an animal model study only. Bruceine D was reported to markedly improve the loss of dopaminergic neurons in the substantia nigra pars compacta and alleviate neuroinflammation through reducing glial activation in an MPTP-induced mouse model of Parkinson's disease; the mechanism of action was associated with improving Nrf2 activation.
Evidence strength: Animal model data only. No human clinical studies have evaluated B. javanica constituents for SMA or Parkinson's disease.
5.7 Anti-obesity / Lipolytic Activity
Brucein A, Brucein B, Brucein C, 3′-hydroxybrucein A, Brusatol, and Bruceantinol have been reported in the literature to exhibit lipolytic activity. Although the specific mechanism of action is still unclear, these metabolites have shown promising potential in the prevention and treatment of obesity.
Evidence strength: In vitro (adipocyte) data only; entirely preliminary.
5.8 Antiparasitic and Insecticidal Activity
The anti-insect effects of B. javanica mainly include anti-Plasmodium, anti-Babesia, anti-Trypanosoma, and the ability to kill Culex fumigatus. In Chinese herbal medicine, the kernels are prescribed in amoebic dysentery and as a remedy for intestinal worms.
5.9 Antifungal Activity
The B. javanica extract showed antifungal properties against oral candida in vitro, suggesting that it might be helpful as a treatment for fungal infections.
Evidence strength: In vitro only.
6. Body Systems and Health Areas Associated with Brucea javanica
- Digestive system: Amoebic dysentery, diarrhea, intestinal inflammation, intestinal worms, abdominal pain (traditional use backed by preclinical data)
- Oncology / hematology: Multiple solid tumors (lung, gastric, liver, cervical, colorectal, pancreatic) and hematologic malignancies (leukemia) — adjuvant BJOE use in Chinese clinical practice; preclinical data for isolated compounds
- Infectious diseases: Malaria (traditional and preclinical evidence); trypanosomiasis (preclinical); hepatitis B virus (in vitro evidence); fungal infections (in vitro)
- Endocrine / metabolic: Type 2 diabetes / blood glucose regulation (animal model data)
- Musculoskeletal / neuromuscular: Spinal muscular atrophy (animal model data)
- Neurological: Parkinson's disease neuroinflammation (animal model data)
- Dermatology: Warts and corns (traditional external application)
- Immunology: Immune enhancement in cancer patients receiving chemoradiotherapy (clinical observational data)
7. Dosage Forms and Reported Dosages
B. javanica encompasses a diverse range of metabolites and various formulations and has been commercially available in many forms, such as BJOE injection, BJO oral emulsion, and BJO soft capsules.
The following dosages are reported in the source literature:
- BJOE combined with TACE (liver cancer): BJOE at 30 ml/day combined with TACE was the dosage used in the meta-analysis that showed significantly increased overall efficacy and 2-year survival rate compared to TACE alone.
- Ethyl acetate fraction (animal antidiabetic model): Rats treated with the ethyl acetate fraction at 125 mg/kg body weight showed a 39.91% decrease in blood glucose levels at 30 min during oral glucose tolerance test.
- Bruceines E and D (animal blood glucose model): Normoglycaemic mice administered with 1 mg/kg of bruceines E and D exhibited significant blood glucose concentration reductions of 40.07 ± 11.45% and 48.82 ± 13.34%, respectively.
- Anti-inflammatory animal study: Oral intake of 50 mg/kg of the ethanolic extract exhibited anti-inflammatory activity, inhibiting rat paw edema by 50.91%.
- In vitro anti-HBV: BJOE at concentrations at or below 5 mg/ml was nontoxic to carcinoma cell lines while significantly inhibiting HBV replication.
No standardized human dosing recommendations have been established in the Western regulatory literature (EMA, NIH ODS, or USP) for any indication. All dosing data outside of the BJOE injection clinical context derives from preclinical studies and should not be extrapolated to human use without further clinical validation.
8. Safety Considerations and Interactions
8.1 Pharmacopeial Acknowledgment of Toxicity
The 2015 edition of the Chinese Pharmacopoeia reported that Brucea javanica has some toxicity. BJOEI can result in allergic reactions, phlebitis, liver damage, kidney damage, and arrhythmia.
8.2 Adverse Effects Observed in Clinical Studies
Some patients may experience phlebitis, muscular soreness, low-grade fever, or occasional skin rashes. In addition, there was no significant hepatic, renal, or cardiac dysfunction reported between the IBJOE and control groups in one review of lung cancer studies, though the authors noted this observation was limited by the quality of the original study reports.
The gastric cancer meta-analysis reported that BJOEI as an adjunct to chemotherapy was associated with reduced incidence of several chemotherapy-related adverse effects, including neutropenia and peripheral neuropathy; however, as noted above, evidence quality was rated low by GRADE criteria.
8.3 Inherent Cytotoxicity and Brusatol Specificity Debate
Many studies have explored the antitumor mechanisms of quassinoid brusatol, revealing that brusatol inhibits protein synthesis, activates the nuclear translocation of NF-κB, and downregulates the protein levels of the proto-oncogene C-MYC. However, in 2011, Ren et al. reported contrasting findings, indicating that brusatol alone does not demonstrate anticancer activity but effectively inhibits the Nrf2 pathway and improves the efficacy of cisplatin. This mechanistic ambiguity has important implications for clinical translation.
Although targeting specificity and systemic toxicity remain issues, numerous findings have shown that targeting the NRF2 defensive mechanism could be a novel therapeutic strategy for human malignancies. The broad NRF2 inhibition by brusatol raises concerns that it could impair cytoprotective antioxidant responses in normal tissues, a toxicological risk that has not been fully characterized in human subjects.
8.4 Herb–Drug Interactions
Many patients use traditional Chinese medicine as a complementary treatment to alleviate adverse effects and improve therapeutic efficacy. However, predicting herb–drug interactions remains challenging, and ensuring the safety of such combinations also remains challenging. The combination of BJOE with cisplatin, in particular, has been studied from a pharmacokinetic standpoint given brusatol's inhibition of the Nrf2 pathway, which modulates cellular defense against cisplatin-induced nephrotoxicity.
8.5 Limitations of the Evidence Base
Many systematic reviews or meta-analyses have been published to evaluate the efficacy and safety of BJOE. Nevertheless, uneven quality made it difficult to reach a consensus, and there has been no specific review to integrate the evidence of BJOEI for cancer at the highest evidentiary level. There have long been arguments regarding the mechanism and specificity of brusatol, which limits the further development and advancement of this compound into clinical practice.
References
Go back